Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use- Electronic Spanish Platform
Launched by BAYLOR RESEARCH INSTITUTE · Jul 25, 2022
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This Phase II study seeks to conduct further research to validate the TAPS-ESP as a Spanish language version of the screening and brief assessment and pave the way for its broad dissemination in the healthcare system. The investigators will use a novel application of a Type 1 hybrid effectiveness-implementation design, adapted to a screening validation study. The investigators will conduct a large-scale study to validate the TAPS-ESP against established diagnostic and biomarker metrics, replicating the design of the seminal English-language TAPS study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 or older
- • Current patient of the clinic
- • Spanish-language preferred
- • Ability to read Spanish
- Exclusion Criteria:
- • Unable to provide informed consent
- • Inability to comprehend or read Spanish
- • Inability to self-administer the iPad tool due to physical limitations
About Baylor Research Institute
Baylor Research Institute (BRI) is a leading clinical research organization affiliated with Baylor Scott & White Health, dedicated to advancing medical knowledge and improving patient care through innovative research initiatives. With a focus on translational medicine, BRI conducts a wide range of clinical trials across various therapeutic areas, including cardiovascular, oncology, and neurology. The institute is committed to fostering collaborative partnerships with academic institutions, industry leaders, and healthcare professionals to enhance the development of novel therapies and interventions. Through rigorous scientific methodology and ethical standards, Baylor Research Institute strives to contribute significantly to the advancement of healthcare and to provide patients with access to cutting-edge treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Patients applied
Trial Officials
Katherine Sanchez, PhD
Principal Investigator
Baylor Scott and White Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials